Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 12 2024 | Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management Industry News In The News Industry Read More Sep 10 2024 | The Case for Integrating Novel Device-Based Therapies into Guideline Directed Medical Therapy for the Treatment of Heart Failure HFSA News Clinical Document Press Release Research Read More Sep 8 2024 | HFSA President's Update: September 2024 HFSA News President's Updates Read More Sep 3 2024 | Welcoming August's New HFSA Members HFSA News Membership Read More Sep 3 2024 | ESC 2024: Late-Breaking KERENDIA® (finerenone) Investigational Data Showed a Statistically Significant Reduction in the Composite Outcome of Cardiovascular Death and Total Heart Failure Events Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Sep 12 2024 | Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management Industry News In The News Industry Read More
Sep 10 2024 | The Case for Integrating Novel Device-Based Therapies into Guideline Directed Medical Therapy for the Treatment of Heart Failure HFSA News Clinical Document Press Release Research Read More
Sep 3 2024 | ESC 2024: Late-Breaking KERENDIA® (finerenone) Investigational Data Showed a Statistically Significant Reduction in the Composite Outcome of Cardiovascular Death and Total Heart Failure Events Industry News In The News Industry Read More
